Mesoblast Financial Results and Corporate Update Webcast
Rhea-AI Summary
Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced a webcast to discuss their full-year financial results and operational highlights for the period ending June 30, 2025.
The webcast is scheduled for Thursday, August 28 at 6:30 PM EDT (Friday, August 29, 8:30 AM AEST). Investors can access the webcast through the company's provided link, and a recording will be available on Mesoblast's investor relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, MESO gained 0.75%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $2.04B at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025.
The webcast will begin at 6.30pm EDT, Thursday, August 28; 8.30am AEST, Friday, August 29, 2025. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2025/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | |
| Allison Worldwide | |
| Emma Neal | |
| T: +1 603 545 4843 | |
| E: emma.neal@allisonworldwide.com | |
| Media – Australia | |
| BlueDot Media | |
| Steve Dabkowski | |
| T: +61 419 880 486 | |
| E: steve@bluedot.net.au |
FAQ
When is Mesoblast's (MESO) FY2025 earnings webcast?
How can investors access Mesoblast's (MESO) FY2025 earnings webcast?
What will be discussed in Mesoblast's (MESO) upcoming webcast?
What is Mesoblast's (MESO) main business focus?
